Previous studies and speculations pointed to inadequate training and lack of interest as reasons behind fewer care settings and services among newer doctors. A recent study refutes this hypothesis.
Results show no difference in risk of stroke, myocardial infarction or pulmonary embolism with Pfizer monovalent versus Pfizer bivalent COVID-19 boosters.
Noticeably absent from the NDP leader’s recent speech, and from the 2023-24 spending plan, was any mention of one of his party’s biggest priorities: pharmacare.
